ABIONYX Pharma is a new biotech company dedicated to the discovery and development of innovative therapies for
patients. The biotech assets from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of
cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery
platform in oncology, more specifically in immuno-oncology and chemotherapy, as well as molecules targeted for other
indications.